Neurocrine biosciences announces initiation of phase 1 clinical study evaluating effects of nbi-1076986 in healthy adults

San diego , may 9, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the initiation of its phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1076986 in healthy adult participants. nbi-1076986 is an investigational, oral, m4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by neurocrine biosciences.
NBIX Ratings Summary
NBIX Quant Ranking